Skip to main
MLYS
MLYS logo

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. has demonstrated significant efficacy of its product candidate, lorundrostat, in reducing blood pressure, achieving a robust placebo-adjusted reduction of 9.1 mmHg at six weeks and 11.7 mmHg at twelve weeks in clinical trials. The positive safety profile, including a low incidence of hyperkalemia at 1.1%, and the potential for daily use in patients with uncontrolled and resistant hypertension, enhance the attractiveness of lorundrostat as a viable treatment option. This combination of strong clinical outcomes and the ability to offer a differentiated mechanism of action positions Mineralys favorably for future growth and development within the biopharmaceutical market.

Bears say

Mineralys Therapeutics Inc reported a net loss of $48.9 million for the fourth quarter of 2024, and a total net loss of $177.8 million for the full year, translating to losses of $0.98 and $3.66 per share, respectively. The company faces significant risks, including the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates, which may stem from limitations related to market size, penetration rates, and pricing strategies. Additionally, the company's ability to secure necessary capital resources for ongoing operations and program development poses a critical challenge to its financial stability and long-term viability.

MLYS has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 8 analysts, MLYS has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.